Study on the serum cystatin C in the elderly population with metabolic syndrome

doi:10.3969/j.issn.1006-7795.2017.04.010

Abstract

Abstract: Objective To investigate the change of serum cystatin C level and its relationship with metabolic syndrome (MS) main components and homeostasis model assessment of insulin resistance (HOMA-IR) in elderly population with MS. Methods A total of 404 Beijing elderly inhabitants (>60 years, age ranged 60-88 years) and 60 control persons (≤60 years, age ranged 35-60 years) without MS components were enrolled into the present study, and the data including MS components, fasting insulin (FINS), serum creatinine (SCr) and cystatin C were tested and some parameters such as HOMA-IR and estimated glomerular filtration rate (eGFR) were measured; according to MS criteria defined by Chinese Diabetes Society, the elderly subjects were divided in to MS and non-MS, and the groups with abnormal MS components, respecitively. Results Cystatin C indicated no significant differences between male and female(P>0.05), and higher in MS than in non-MS(1.10±0.25 vs 1.02±0.25, P<0.01). Furthermore, with the graded increase of MS components, serum cystatin C showed a progressive rise, with its sensitivity higher than that of SCr and eGFR; In addition, the multiple regression (Stepwise method) showed that the body mass index (BMI), triglyceride (TG) and HOMA-IR were also the independent influencing factors of serum cystatin C. Conclusion With the deterioration of the metabolic abnormality of the study population, serum cystatin C showed an increasing tendency and it may be taken as a screening marker of early nephropathy and a predicting index of cardiovascular disease (CVD) in MS population.

Key words: metabolic syndrome, cystatin C, early nephropathy

CLC Number:

R589

Zhang Kun, Zhang Chanyuan, Chen Jian, Lu Binghuai. Study on the serum cystatin C in the elderly population with metabolic syndrome[J]. Journal of Capital Medical University, 2017, 38(4): 535-540.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.04.010

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I4/535

References

[1] Huh J H, Yadav D, Kim J S, et al, An association of metabolic syndrome and chronic kidney disease from a 10-year prospective cohort study[J]. Metabolism, 2017,67:54-61.
[2] Martin A, Neale E P, Batterham M, et al. Identifying metabolic syndrome in a clinical cohort: Implications for prevention of chronic disease [J]. Prev Med Rep,2016,4:502-506.
[3] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议 [J]. 中华糖尿病杂志, 2004, 12(3): 156-161.
[4] Angelidis C, Deftereos S, Giannopoulos G, et al. Cystatin C: an emerging biomarker in cardiovascular disease[J]. Curr Top Med Chem,2013,13(2):164-179.
[5] Hart A, Blackwell T L, Paudel M L, et al. Cystatin C and the risk of frailty and mortality in older men [J]. J Gerontol A Biol Sci Med Sci, 2017,72(7):965-970.
[6] Luo J, Wang L P, Hu H F, et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis[J]. Clin Chim Acta,2015,450:39-45.
[7] 马迎春, 左力, 王梅, 等. 肾小球滤过率评估方程在慢性肾脏病不同分期中的适用性 [J]. 中华内科杂志, 2005, 44(4): 285-289.
[8] Chen J, Kong X, Jia X, et al. Association between metabolic syndrome and chronic kidney disease in a Chinese urban population[J]. Clin Chim Acta, 2017, 470:103-108.
[9] 陈勇,魏云,列前程,等. 24小时尿微量清蛋白和血清胱抑素C联合检测在糖尿病肾损伤早期诊断中的应用价值 [J]. 国际医学检验, 2011, 32(2): 262-263.
[10] Asefy Z, Mirinejad M, Amirrasooli H, et al. Assessing validity of serum cystatin C for predicting metabolic syndrome[J]. Pak J Biol Sci, 2014, 17(4):582-585.
[11] Moura Rdo S, Vasconcelos D F, Freitas E, et al. Cystatin C, CRP, log TG/HDLc and metabolic syndrome are associated with microalbuminuria in hypertension[J]. Arq Bras Cardiol,2014,102(1):54-59.
[12] Shlipak M G, Wassel Fyr C L, Chertow G M, et al. Cystatin C and mortality risk in the elderly: the health, aging, and body composition study[J]. J Am Soc Nephrol, 2006,17(1):254-261.
[13] Luc G, Bard J M, Lesueur C, et al. Plasma cystatin-C and development of coronary heart disease: The PRIME Study[J]. Atherosclerosis,2006,185(2):375-380.
[14] Larsson A, Helmersson J, Hansson L O, et al. Serum cystatin C is associated with other cardiovascular risk markers and cardiovascular disease in elderly men[J]. Int J Cardiol, 2008,125(2):263-264.
[15] Arpegård J, Ostergren J, de Faire U, et al. Cystatin C-a marker of peripheral atherosclerotic disease? [J]. Atherosclerosis,2008,199(2):397-401.
[16] Ying X, Jiang Y, Qin G, et al. Association of body mass index, waist circumference, and metabolic syndrome with serum cystatin C in a Chinese population[J]. Medicine (Baltimore), 2017,96(10):e6289.
[17] Huang R, Gu J, Cao Q, et al. The association between serum cystatin C and carotid intima-media thickness in metabolic syndrome patients with normal estimated glomerular filtration rate[J]. Clin Chim Acta, 2015,448:170-173.
[18] 黄菁, 郑美玲,王玉珏,等.尿肾损伤分子1、血清胱抑素C和尿中性粒细胞明胶酶相关性脂质运载蛋白预测子痫前期发病和早期肾损伤的价值[J].中国医科大学学报,2016,45(5):460-463.
[19] 田晓,徐湜潺,冯晓明,等.血清脂联素与胱抑素C检测在糖尿病肾病早期诊断中的价值[J].中国煤炭工业医学杂志, 2014,17(2):248-250.
[20] Pham H, Robinson-Cohen C, Biggs M L, et al. Chronic kidney disease, insulin resistance, and incident diabetes in older adults[J].Clin J Am Soc Nephrol, 2012,7(4):588-594.
[21] Zhang X, Lerman L O. The metabolic syndrome and chronic kidney disease[J]. Transl Res,2017,183:14-25.
[22] Ix J H, Shlipak M G, Chertow G M, et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study[J]. Circulation,2007,115(2):173-179.
[23] Retnakaran R, Connelly P W, Harris S B, et al. Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in aboriginal youth[J]. Pediatr Nephrol, 2007,22(7):1007-1013.